Immunodominance and tumor escape

H Schreiber, TH Wu, J Nachman, WM Kast - Seminars in cancer biology, 2002 - Elsevier
Cancers in mouse and man express multiple tumor-specific as well as tumor-associated
antigens. Immunodominance in the host response to these antigens can result in successive …

Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia

AS Kadish, GYF Ho, RD Burk… - Journal of the …, 1997 - academic.oup.com
Background: Infection with human papillomavirus (HPV) type 16 (HPV16) is a major cause
of high-grade cervical intraepithelial neoplasia (CIN). Experiments were planned to evaluate …

Cervical cancer vaccines: emerging concepts and developments

DM Da Silva, GL Eiben, SC Fausch… - Journal of cellular …, 2001 - Wiley Online Library
Certain human cancers are linked to infection by oncogenic viruses that are able to cause
transformation of the normal host cell into a cancerous cell. Human papillomavirus (HPV) …

Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B‐fragment of Shiga toxin

RS Lee, E Tartour, P Van der Bruggen… - European journal of …, 1998 - Wiley Online Library
Targeting exogenous antigen into the MHC class I‐restricted presentation pathway is a
prerequisite for the induction of cytotoxic T lymphocytes (CTL) which have been shown to …

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

R Gavioli, E Gallerani, C Fortini, M Fabris… - The Journal of …, 2004 - journals.aai.org
Tat, the trans activation protein of HIV, is produced early upon infection to promote and
expand HIV replication and transmission. However, Tat appears to also have effects on …

Advances in peptide-based human papillomavirus therapeutic vaccines

TY Liu, WM Hussein, I Toth… - Current topics in …, 2012 - ingentaconnect.com
Cervical cancer is the second leading cause of cancer in women worldwide. Human
papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial …

Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model

BW Tillman, TL Hayes, TD deGruijl, JT Douglas… - Cancer research, 2000 - AACR
Dendritic cells (DCs) represent a unique junction from which to initiate antigen-specific
immunity. One of the most challenging obstacles for DC-based immunotherapy has been the …

[HTML][HTML] Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T cell immunotherapy for triple negative breast cancer: a …

SR Burkholz, CV Herst, RT Carback, PE Harris… - Vaccines, 2023 - mdpi.com
A triple negative breast cancer model using the murine 4T1 tumor cell line was used to
explore the efficacy of an adjuvanted survivin peptide microparticle vaccine using tumor …

Cervical cancer vaccines: recent advances in HPV research

GL Eiben, DM Da Silva, SC Fausch, IC Le Poole… - Viral …, 2003 - liebertpub.com
Carcinomas of the anogenital tract, particularly cancer of the cervix, account for almost 12%
of all cancers in women, and so represent the second most frequent gynecological …

Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions

S Kanodia, DM Da Silva… - International journal of …, 2008 - Wiley Online Library
Human papillomavirus (HPV)‐induced lesions are distinct in that they have targetable
foreign antigens, the expression of which is necessary to maintain the cancerous phenotype …